


REGISTERED COMPANY NUMBER: 11943477 (England and Wales)
REGISTERED CHARITY NUMBER: 1185091

**Report of the Trustees and
Audited Financial Statements
for the Year Ended 31 December 2022
for
Follicular Lymphoma Foundation
(A Company Limited by Guarantee)**



Haines Watts
Chartered Accountants and Statutory Auditor
New Derwent House
69-73 Theobalds Road
London
WC1X 8TA

Follicular Lymphoma Foundation
Contents of the Financial Statements
for the year ended 31 December 2022

	Page
Reference and Administrative Details	1
Report of the Trustees	2 to 7
Report of the Independent Auditors	8 to 10
Statement of Financial Activities	11
Statement of Financial Position	12
Statement of Cash Flows	13
Notes to the Statement of Cash Flows	14
Notes to the Financial Statements	15 to 22

Follicular Lymphoma Foundation
Reference and Administrative Details
for the year ended 31 December 2022

Trustees	Lord J N Mendelsohn Lady N S Mendelsohn Lord R I Harrington P M V Thompson A Wong J J Burley (appointed 15/7/2022) Dr J W Simons (appointed 15/7/2022)
Registered office	New Derwent House 69-73 Theobalds Road London WC1X 8TA
Registered company number	11943477 (England and Wales)
Registered charity number	1185091
Auditors	Haines Watts Chartered Accountants and Statutory Auditor New Derwent House 69-73 Theobalds Road London WC1X 8TA



The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the Year to 31 December 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

1. Objectives and activities

Our mission is to help those with Follicular Lymphoma, a currently incurable blood cancer, to live well and get well by finding and funding the best research to find breakthroughs that will change how we understand and treat the condition. We provide Follicular Lymphoma focused information resources for patients and work to ensure patients' voices are at the heart of the search for better treatments and cure.

More specifically, the Charities objectives are restricted to the following:

1. To sponsor basic and translational research to assist in the development of better treatments and a cure for Follicular Lymphoma including sponsoring the establishment of an international challenge to scientific and clinical researchers to focus on prospective cures.
2. To support the promotion of the "patient voice", by supporting patient advocacy and education, the development of patient communities and evaluating the efficacy of patient reported outcomes on current treatments and side effects to assist clinicians and patients.
3. To improve health outcomes by way of stimulating research and evaluation of complementary conditions to supplement medical treatment.

2. Achievements

New leadership to guide our mission

In July, we welcomed accomplished CEO Kate Rogers to lead our organization into the future. Kate brings exceptional vision and expertise to advance our strategic direction and drive our mission forward. Her passion and leadership have us poised for even greater achievements ahead.

Establishing esteemed advisory boards

Recognising the importance of diverse perspectives, we established new Life Science and Lymphoma/ Informatics Advisory Boards. These boards provide invaluable guidance to enhance our research and development initiatives, with a focus on the Precision Medicine Programme. Their multidisciplinary insights help explore innovative approaches to advancing our understanding of follicular lymphoma.

Strengthening our board of trustees

We warmly welcomed Jess Burley and Jonathan Simons as new trustees in autumn 2022. Their knowledge and experience further enrich our board and contribute diverse viewpoints to propel our mission.

Announcing inaugural CURE FL Award recipients

In December, we marked a significant milestone by announcing the first-ever CURE FL Award recipients. This achievement signals meaningful progress in our commitment to accelerate research and find a follicular lymphoma cure. The CURE FL Awards are not your typical grants; they are a catalyst for change in follicular lymphoma research. Our aim is to accelerate breakthroughs for direct patient benefit, fostering innovation that transforms the FL treatment landscape. Through collaboration, we are bringing researchers together, sharing insights, sparking new ideas, and expediting impactful discoveries for FL patients.

Connecting with global experts at ASH 2022

Our presence at the American Society of Haematology (ASH) conference provided an impactful opportunity to connect with the lymphoma community. We exchanged insights, forged collaborations, and shared our dedication to advancing lymphoma knowledge and patient outcomes through initiatives. We also used this opportunity to reveal to the wider research community our work on the PMP.

3. Strategic report

The Follicular Lymphoma Foundation is an international effort to find and accelerate cures and speed the delivery of precision-based treatments for this little-known cancer.

Follicular Lymphoma Foundation
Report of the Trustees
for the year ended 31 December 2022



The Foundation launched publicly in November 2019 and has been focused on developing its strategy and laying the framework for a hugely exciting programme of work.

None of this would have been possible without the extraordinary support of the hundreds of individuals who have donated to the Foundation to help achieve our goal.

3.1 Charitable activities

3.1.1 Strategy

Over the course of the year the FLF harnessed its global network to develop a strategic approach and framework. The Foundation created a programmatic plan based on two pillars:

- Pillar 1: The Patient & Precision Medicine Programme to harness the power of patients and the patient community in the development of cures and new precision medicine approaches.
- Pillar 2: The Targeted Accelerated Research Programme to invest in only the most promising international FL research and clinical trials.

3.1.2 Partnerships

One of the Foundation's core working principles is to avoid duplication and bring added value to the field by forging partnerships to complement existing programmes, drive better outcomes and create impact.

Partnerships were established during this year with research institutions, other non-profits and commercial entities.

3.1.3 Information Provision and Public Awareness Raising

The launch of the FLF raised awareness of the disease with the general public and helped link people living with FL with sources of information and support.

As part of the launch the Foundation developed a new website as a trusted source of information for FL patients and a more dedicated Patient Hub for FL Patients and families. This was the world's first website dedicated exclusively to Follicular Lymphoma.

3.2 Financial review

3.2.1 Financial position

The Financial accounts for the 12 months period show a deficit of £223,905 and the charity is well-positioned to increase its activities in the future.

3.2.2 Reserves policy

At 31 December 2022, unrestricted reserves were £1,191,921 and restricted reserve had a negative balance of £16,401. The charity is expecting to receive £200,000 of restricted income in 2023 clearing negative balance of £16,401.

The organisation operates with limited overheads. The Trustees have determined that the reserves target should be at the level of 3 months' expected expenditure. Budgeted expenditure in the 2023 financial year is in excess of £2m, and the Trustees have set a targeted reserves figure of £500k as at 31 December 2022.

3.3 Going concern

The Trustees consider that it is appropriate to prepare the financial statements on a going concern basis. The going concern assumption is based on an existing business plan and budget in place covering the period to December 2023. A new 3-year budget/forecast is being drafted which will reduce external contract costs and will substantially reduce annual deficits.

In addition, the Trustees continue to investigate opportunities to enhance the long-term sustainability of the charity and identify those areas where the financial performance can be improved, with actions being taken to reduce the deficits. The establishment of a highly skilled team of permanent employees demonstrates Follicular Lymphoma Foundation's commitment to the operation of the Charity as a going concern. As a result of these factors the Trustees consider the going concern basis to be appropriate.



3.4 Principal risks and uncertainties

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

The trustees have assessed major risks to which the charity is exposed and are satisfied that systems are in place to mitigate exposure to such major risks.

Procedures are in place to ensure compliance with health and safety of staff, volunteers, clients, and visitors to the organisation. The Charity has the appropriate level of insurance to meet its obligations in respect of employees and members of the public and otherwise has a business continuity plan to cover extreme eventualities.

3.5 Future plans

3.5.1 Plans for the next 12 Months

Our areas of focus:

- **Delivering impact through focused research.**
Closing the gaps in FL research and drug development through the dual approach of the provision 'evidence-based' FL information and investing in the most promising curative research.
Developing new treatments and cures to FL patients by creating a pathway with rapid 'bench-to-bedside' developments.
- **Collaborating with the best.**
Relationships are key to the success of the charity. We will map existing and new opportunities for partnerships at an international level, building on critical relationship links with medical experts, scientific researchers, and philanthropic donors.
- **Growing fundraising income.**
Raising funds is essential to ensuring our strategic medical programmes go ahead and that we have the financial resources available to carry out the necessary scientific research to find a cure. We strive to maintain and build fundraising streams where possible whilst also identifying new or different opportunities to drive fundraising.

3.5.2 Precision Medicine Programme (PMP)

The Precision Medicine Programme (PMP) harnesses the power of the follicular lymphoma community to drive research and clinical advances.

Accelerating progress towards a cure

Our mission through the PMP is to unlock the potential of bespoke, precision medicine for FL patients, revolutionising treatment options and propelling us closer to finding a cure. By leveraging real-world data, including biological information, we seek to pioneer new avenues in FL research and drive biopharmaceutical and industry drug development.

Understanding unique biology for personalised therapy

At the core of the PMP is understanding each patient's distinct biology and utilising this knowledge to predict the most effective, tailored therapeutic options.

"The Precision Medicine Programme will be a unique resource of great value to researchers and ultimately to patients, enabling and accelerating biologic and clinical research and trials, and ultimately finding a cure for FL."

Dr Mitchell Smith, Chief Medical Officer.

Top research priorities

Working with partners worldwide, we identified key PMP objectives to address unmet follicular lymphoma needs:

- Understand disease heterogeneity.
- Optimise treatment regimens and sequencing.
- Profile and predict treatment toxicity.
- Develop surrogate endpoints (for improved clinical trial design)
- Generate prospective real-world data.

Comprehensive information for FL

This project hinges on amassing the largest repository of information on FL, providing doctors, researchers, and patients with a newfound understanding of the disease. By leveraging this vast dataset, we can drive forward progress and transform the landscape of FL research and treatment.



3.5.3 Targeted Accelerated Research (TAR) programmes

One key area for the FLF is therapeutic development initiatives, which can accelerate advanced and translational research. To date, the progress in the treatment of FL has been frustratingly slow, with little funding and attention. Our suite of Targeted Accelerated Research (TAR) initiatives aim to make curative therapies available to FL patients as soon as possible. Our TAR programmes enhance our progress towards our mission by investing in the highest calibre research promising immediate benefit to the patient (CURE FL Awards); creating strategic partnerships with top investigators and institutes around the world (Centres of Excellence); and ensuring we don't miss out on unique high-risk, high-reward opportunities (Opportunity Fund).

A. CURE FL Awards Programme

The CURE FL Awards, launched in 2022, are a unique research grant program bringing together top clinical scientists and researchers worldwide. Through innovative projects, we aim to swiftly advance toward clinical trials and effective new therapies for patients.

Addressing the need for more follicular lymphoma research

Follicular lymphoma is often overshadowed compared to other lymphomas, due to perceived slower progression and trial complexities. The CURE FL Awards give this disease a voice and drive urgently needed treatment advances.

Meet the 2022 grantees

In collaboration with Milken Institute, we carefully selected proposals targeting key follicular lymphoma needs while prioritising patient interests and clinical application. After a thorough 5-month review involving experts and patients, we identified the most promising projects out of 20 worldwide proposals.

We are thrilled to introduce our first grantees and their exciting research areas. Each has been awarded up to \$500K over two years, beginning December 2022. This significant investment marks an initial stride toward our mission.

The Follicular Lymphoma Foundation is honoured to support the critical work of the following pioneering researchers who were selected as the inaugural CURE FL Awards grantees in December 2022:

- **Dr Hans-Guido Wendel, Memorial Sloan Kettering Cancer Center, US:** A new signal mechanism (HVEM/BTLA) abnormal in 90% of FL cases and important in the genesis of FL has been identified by Dr Wendel and his group. This makes HVEM/BTLA a high-value target specific to FL. CAR-T cells that attack all B cells are an exciting new treatment for FL. This study will use CAR-T in a different way, to specifically attack this FL-specific pathway. The goal is to have a clinical trial of these novel CAR-T cells open for patients by the end of the grant period.
- **Dr Joshua Brody, Icahn School of Medicine at Mount Sinai, US:** CAR-T cells are an excellent treatment for some patients with FL, but do not work for everyone. Dr Brody, an expert in immunotherapy of lymphoma, and his team have evidence that bystander cells that do not express the CAR-T target are one mechanism of CAR-T resistance, and that they may have a way to overcome this. Their study may well lead to a clinical trial of CAR-T given with a drug that will enhance the killing of these bystander cells, improving outcomes for patients.
- **Dr Wendy Béguélin, Weill Cornell Medicine, US:** Dr Béguélin, an expert in lymphoma biology, along with her clinical collaborators, will conduct trials combining epigenetic-targeted EZH2 inhibitors with immunotherapy (CAR-T or bispecific antibodies), or with apoptosis-targeted BCL2 inhibitors. Using unique FL mouse models and patient samples, she will study combinations of targeted therapies with immunotherapy, including impact on both FL B cells and its microenvironment. The plan is to define effective combinations to improve therapy in FL.
- **Dr Patricia Pérez-Galán, Fundació Clínic per a la Recerca Biomèdica, Spain:** Leading this Spanish group with extensive clinical experience developing CAR-T cell treatment for lymphoma. They will develop new generation dual-targeted CAR-T cells, cells that target not only lymphoma cells but also the surrounding microenvironment that helps keep FL cells alive. They hope to have a clinical trial of the best CAR-T ready by the end of the grant period.



Accelerating progress and impact

By allocating \$2 million over two years, the CURE FL Awards propel us closer to better treatments and a cure. We aim to elevate follicular lymphoma's significance in drug development and catalyse tailored therapies. Our goal is to bring hope, opportunities, and critical treatment insights to patients and clinicians.

B. FLF Centres of Excellence (CoE)

The FLF proudly presents the Centres of Excellence (CoE) programme, an ongoing initiative that forges partnerships with major academic and research institutions worldwide. This programme harnesses the collective expertise of esteemed institutions, spanning various disciplines, to drive advancements in FL research and bring us closer to our mission of finding a cure.

The CoE programme seeks to accelerate transformative change in FL research. By collaborating with leading institutions, we aim to revolutionise FL treatment and generate invaluable insights applicable to a wide range of diseases. A key focus of the programme is expediting breakthroughs in T-cell directed therapies, which hold immense potential to revolutionise clinical care for FL patients.

Sharing knowledge for rapid progress

Collaboration and knowledge sharing are integral to the success of the CoE. We strive to break down academic silos, facilitating an open exchange of information and ideas. By fostering a collaborative environment, we create the conditions necessary for rapid advancements in clinical care for FL patients. Our commitment to sharing knowledge ensures that progress is accelerated and impactful across the entire programme.

Looking ahead: announcing partnerships

As the CoE programme progresses, we are excited to announce new partnerships in the near future driving us closer to our ultimate goal of finding a cure for FL and related cancers.

The programme represents a significant milestone in our ongoing journey to transform the landscape of FL research and treatment. By collaborating with prestigious institutions worldwide, we are poised to make remarkable progress in our mission.

3.6 Structure, governance, and management governing documents

FLF is a private company limited by guarantee.

The company was established on 12 April 2019 under a Memorandum of Association which determines the objects and powers of the charitable company and is governed under its Articles of Association.

The charitable company was registered with the Charity Commission on 29 August 2019.

3.6.1 Decision making

The Board of Trustees meets 5 times per year and is responsible for the strategic direction and policy of the charity and for monitoring the management and outcomes of services. Board members are drawn from a variety of professional backgrounds relevant to the work of the charity.

In 2022, the Board has recruited additional Trustees to strengthen its governance still further in recognition of the growth and diversification of the charity's activities. The Charity appointed its first Chief Executive Officer in July 2022. The Chief Operating Officer is delegated to deal with day-to-day operations.

3.6.2 Statement of trustees' responsibilities

The trustees (who are also the directors of Follicular Lymphoma Foundation for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom

Follicular Lymphoma Foundation
Report of the Trustees
for the year ended 31 December 2022



Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" -

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to

- Select suitable accounting policies and then apply them consistently.
- Observe the methods and principles in the Charity SORP.
- Make judgements and estimates that are reasonable and prudent.
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

So far as the trustees are aware:

- There is no relevant audit information of which the charitable company's auditors are unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

4. Auditors

The auditors, Haines Watts Chartered Accountants, will be proposed for re-appointment at the forthcoming Annual General Meeting.

Report of the trustees, incorporating a strategic report, approved by order of the board of trustees, as the company directors, on..... and signed on the board's behalf by:

Sep 27, 2023

Mendelsohn

Mendelsohn (Sep 27, 2023 00:33 GMT+1)

Lord J N Mendelsohn - Trustee

Report of the Independent Auditors to the Members of Follicular Lymphoma Foundation

Opinion

We have audited the financial statements of Follicular Lymphoma Foundation (the 'charitable company') for the year ended 31 December 2022 which comprise the Statement of Financial Activities, the Statement of Financial Position, the Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2022 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other Information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Trustees has been prepared in accordance with applicable legal requirements.

Report of the Independent Auditors to the Members of Follicular Lymphoma Foundation

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- *adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or*
- *the financial statements are not in agreement with the accounting records and returns; or*
- *certain disclosures of trustees' remuneration specified by law are not made; or*
- *we have not received all the information and explanations we require for our audit.*

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We gained an understanding of the legal and regulatory framework applicable to the company and the industry in which it operates, and considered the risk of acts by the company that were contrary to applicable laws and regulations, including fraud. We discussed with the Directors the policies and procedures in place regarding compliance with laws and regulations. We discussed amongst the audit team the identified laws and regulations, and remained alert to any indications of non-compliance.

During the audit we focussed on laws and regulations which could reasonably be expected to give rise to a material misstatement in the financial statements, including, but not limited to, the Companies Act 2006 and UK tax legislation. Our tests included agreeing the financial statement disclosures to underlying supporting documentation and enquiries with management.

Our procedures in relation to fraud included but were not limited to: inquires of management whether they have any knowledge of any actual, suspected or alleged fraud, and discussions amongst the audit team regarding risk of fraud such as opportunities for fraudulent manipulation of financial statements. We determined that the principal risks related to posting manual journal entries to manipulate financial performance and management bias through judgements in accounting estimates. We also addressed the risk of management override of internal controls, including testing journals and evaluating whether there was evidence of bias by the directors that represented a risk of material misstatement due to fraud.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

**Report of the Independent Auditors to the Members of
Follicular Lymphoma Foundation**

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Haines Watts

Jane Wills (Senior Statutory Auditor)
for and on behalf of Haines Watts
Chartered Accountants and Statutory Auditor
New Derwent House
69-73 Theobalds Road
London
WC1X 8TA

Sep 27, 2023

Date:

Follicular Lymphoma Foundation
Statement of Financial Activities
(Incorporating an Income and Expenditure Account)
for the year ended 31 December 2022

	Notes	Unrestricted funds £	Restricted fund £	2022 Total funds £	2021 Total funds £
Income and endowments from					
Donations and legacies	2	1,984,641	200,000	2,184,641	1,678,785
Investment income	3	<u>1,619</u>	<u>-</u>	<u>1,619</u>	<u>37</u>
Total		<u>1,986,260</u>	<u>200,000</u>	<u>2,186,260</u>	<u>1,678,822</u>
Expenditure on					
Raising funds	4	330,453	-	330,453	106,992
Charitable activities	5				
Direct Expenditure		1,713,332	216,401	1,929,733	457,358
Governance costs		16,302	-	16,302	27,155
Support costs		<u>133,677</u>	<u>-</u>	<u>133,677</u>	<u>44,229</u>
Total		<u>2,193,764</u>	<u>216,401</u>	<u>2,410,165</u>	<u>635,734</u>
NET INCOME/(EXPENDITURE)		(207,504)	(16,401)	(223,905)	1,043,088
Reconciliation of funds					
Total funds brought forward		1,399,425	-	1,399,425	356,337
Total funds carried forward		<u>1,191,921</u>	<u>(16,401)</u>	<u>1,175,520</u>	<u>1,399,425</u>

Continuing operations

All income and expenditure has arisen from continuing activities.

Please Note: Restricted deficit funds carried forward will be covered by committed multiyear gift, second part due in 2023.

Restricted funds

Restricted Deficit funds carried forward of £16,401 will be covered by committed multiyear gift, second part due in 2023.

The notes form part of these financial statements

Follicular Lymphoma Foundation (Registered number: 11943477)

Statement of Financial Position
31 December 2022

	Notes	2022 £	2021 £
Fixed assets			
Tangible assets	11	7,033	5,696
Current assets			
Debtors	12	57,766	22,775
Cash at bank		<u>1,381,442</u>	<u>1,416,474</u>
		1,439,208	1,439,249
Creditors			
Amounts falling due within one year	13	(270,721)	(45,520)
Net current assets		<u>1,168,487</u>	<u>1,393,729</u>
Total assets less current liabilities		<u>1,175,520</u>	<u>1,399,425</u>
NET ASSETS		<u>1,175,520</u>	<u>1,399,425</u>
Funds	16		
Unrestricted funds:			
General fund		1,191,921	1,399,425
Restricted funds:			
Restricted		<u>(16,401)</u>	-
Total funds		<u>1,175,520</u>	<u>1,399,425</u>

The financial statements were approved by the Board of Trustees and authorised for issue on and were signed on its behalf by:

Sep 27, 2023

Mendelsohn

Mendelsohn (Sep 27, 2023 00:33 GMT+1)

J N Mendelsohn - Trustee

The notes form part of these financial statements

Follicular Lymphoma Foundation

**Statement of Cash Flows
for the year ended 31 December 2022**

	Notes	2022 £	2021 £
Cash flows from operating activities			
Cash generated from operations	1	<u>(48,452)</u>	<u>913,908</u>
Net cash (used in)/provided by operating activities		<u>(48,452)</u>	<u>913,908</u>
Cash flows from investing activities			
Purchase of tangible fixed assets		(4,600)	(5,647)
Interest received		<u>1,619</u>	<u>37</u>
Net cash used in investing activities		<u>(2,981)</u>	<u>(5,610)</u>
Change in cash and cash equivalents in the reporting period		<u>(51,433)</u>	<u>908,298</u>
Cash and cash equivalents at the beginning of the reporting period	2	<u>1,416,474</u>	<u>508,176</u>
Cash and cash equivalents at the end of the reporting period	2	<u><u>1,365,041</u></u>	<u><u>1,416,474</u></u>

The notes form part of these financial statements

Follicular Lymphoma Foundation

Notes to the Statement of Cash Flows
for the year ended 31 December 2022

1. Reconciliation of net (expenditure)/income to net cash flow from operating activities			
	2022	2021	
	£	£	
Net (expenditure)/income for the reporting period (as per the Statement of Financial Activities)	(223,905)	1,043,088	
Adjustments for:			
Depreciation charges	3,263	2,578	
Interest received	(1,619)	(37)	
Increase in debtors	(34,991)	(12,864)	
Increase/(decrease) in creditors	<u>208,800</u>	<u>(118,857)</u>	
Net cash (used in)/provided by operations	<u>(48,452)</u>	<u>913,908</u>	
2. Analysis of cash and cash equivalents			
	2022	2021	
	£	£	
Notice deposits (less than 3 months)	1,381,442	1,416,474	
Deficit in restricted reserve	<u>(16,401)</u>	<u>-</u>	
Total cash and cash equivalents	<u>1,365,041</u>	<u>1,416,474</u>	
The charity is expecting to receive £200,000 of restricted income in 2023 clearing negative balance of £16,401.			
3. Analysis of changes in net funds			
	At 1/1/22	Cash flow	At 31/12/22
	£	£	£
Net cash			
Cash at bank	1,416,474	(51,433)	1,365,041
	<u>1,416,474</u>	<u>(51,433)</u>	<u>1,365,041</u>
Total	<u>1,416,474</u>	<u>(51,433)</u>	<u>1,365,041</u>

The notes form part of these financial statements

Follicular Lymphoma Foundation

Notes to the Financial Statements for the year ended 31 December 2022

1. Accounting policies

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Follicular Lymphoma Foundation is a private company limited by guarantee, and a registered charity.

Going concern

The financial statements have been prepared on a going concern basis. The Trustees have reviewed and considered relevant information, including the annual budget and future cash flows in making their assessment. Based on these assessments, and the current resources available, the Trustees have concluded that they can continue to adopt the going concern basis in preparing the annual report and accounts.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Governance costs

Governance costs include costs of the preparation and examination of the statutory accounts, the costs of trustee meetings and the cost of any legal advice on governance matters.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment - 33% on cost

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Follicular Lymphoma Foundation
Notes to the Financial Statements - continued
for the year ended 31 December 2022

1. Accounting policies - continued

Significant judgement and estimates

Preparation of the financial statements requires management to make significant judgements and estimates in determining the carrying amounts of accruals and deferred income. Management makes assumptions of the effects of uncertain future events on those assets and liabilities at the balance sheet date. The management's estimates and assumptions are based on historical experience and expectation of future events and are reviewed periodically. This disclosure excludes uncertainty over future events and judgement in respect of measuring financial instruments.

Management do not consider there to be any material judgements or estimation and uncertainty requiring disclosure.

Financial instruments

Financial assets and financial liabilities are recognised in the balance sheet when the charity becomes a party to the contractual provisions of the instrument.

Other debtors and creditors are classified as basic financial instruments and measured at initial recognition at transaction price. Debtors and creditors are subsequently measured at amortised cost using the effective interest rate method. A provision is established when there is objective evidence that the charity will not be able to collect all amounts due.

Cash and cash equivalents are classified as basic financial instruments and comprise cash in hand and at bank and bank overdrafts which are an integral part of the charity's cash management.

Financial liabilities and equity instruments issued by the charity are classified in accordance with the substance of the contractual arrangements entered into and the definitions of a financial liability and an equity instrument. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities. Equity instruments issued by the charity are recorded at the proceeds received, net of direct issue costs.

2. Donations and legacies

	2022	2021
	£	£
Donations	<u>2,184,641</u>	<u>1,678,785</u>

Donations and legacies include restricted income received of £200,000 for support and advancement to find new treatments and cures for FL, particularly by the development and establishment of a Patient FL Registry and Biobank.

3. Investment income

	2022	2021
	£	£
Deposit account interest	<u>1,619</u>	<u>37</u>

Follicular Lymphoma Foundation
Notes to the Financial Statements - continued
for the year ended 31 December 2022

4. Raising funds

Raising donations and legacies

	2022	2021
	£	£
Staff costs	86,929	37,023
Marketing and Communications	8,233	20,492
Event costs	3,254	-
Consultancy	99,069	24,465
IT and support costs	25,403	2,580
Allocation of overheads	69,836	-
Travel	1,926	469
Event costs	10,966	20,659
Fundraising fees	<u>12,950</u>	<u>1,304</u>
	<u>318,566</u>	<u>106,992</u>

Investment management costs

	2022	2021
	£	£
Administrative expenses	<u>11,887</u>	<u>-</u>
Aggregate amounts	<u>330,453</u>	<u>106,992</u>

5. Charitable activities costs

	Direct Costs £	CURE FL grant award (see note 6) £	Support costs (see note 7) £	Totals £
Direct Expenditure	756,834	803,501	369,398	1,929,733
Governance costs	-	-	16,302	16,302
Support costs	<u>-</u>	<u>232,294</u>	<u>(98,617)</u>	<u>133,677</u>
	<u>756,834</u>	<u>1,035,795</u>	<u>287,083</u>	<u>2,079,712</u>

6. CURE FL grant award

	2022	2021
	£	£
CURE FLF Grant award	803,501	-
CURE FL Management costs	<u>232,294</u>	<u>-</u>
	<u>1,035,795</u>	<u>-</u>

The total grants paid to institutions during the year was as follows:

	2022	2021
	£	£
General fund	<u>1,035,795</u>	<u>-</u>

Follicular Lymphoma Foundation
Notes to the Financial Statements - continued
for the year ended 31 December 2022

7. Support costs

	Management £	Finance £	Other £	Governance costs £	Totals £
Direct Expenditure	382,685	-	-	(13,287)	369,398
Governance costs	-	-	-	16,302	16,302
Support costs	<u>(204,184)</u>	<u>13,811</u>	<u>(39,353)</u>	<u>131,109</u>	<u>(98,617)</u>
	<u>178,501</u>	<u>13,811</u>	<u>(39,353)</u>	<u>134,124</u>	<u>287,083</u>

8. Net income/(expenditure)

Net income/(expenditure) is stated after charging/(crediting):

	2022 £	2021 £
Auditors' remuneration	15,056	17,251
Depreciation - owned assets	3,263	2,578
Hire of plant and machinery	<u>367,810</u>	<u>-</u>

9. Trustees' remuneration and benefits

There were no trustees' remuneration or other benefits for the year ended 31 December 2022 nor for the year ended 31 December 2021.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 December 2022 nor for the year ended 31 December 2021.

Donations from Trustees'

During the period the total aggregate amount of donations from Trustees was £9,000 (2021: £10,000).

10. Staff costs

The average number of employees during the year was 5 (2021 - 4).

The average monthly number of employees during the year was as follows:

	2022	2021
Admin	<u>5</u>	<u>4</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2022	2021
£60,001 - £70,000	-	1
£70,001 - £80,000	-	1
£80,001 - £90,000	1	-
£101,000 - £110,000	<u>1</u>	<u>-</u>
	<u>2</u>	<u>2</u>

Follicular Lymphoma Foundation
Notes to the Financial Statements - continued
for the year ended 31 December 2022

11. Tangible fixed assets

	Computer equipment £
Cost	
At 1 January 2022	10,216
Additions	<u>4,600</u>
At 31 December 2022	<u>14,816</u>
Depreciation	
At 1 January 2022	4,520
Charge for year	<u>3,263</u>
At 31 December 2022	<u>7,783</u>
Net book value	
At 31 December 2022	<u>7,033</u>
At 31 December 2021	<u>5,696</u>

12. Debtors: amounts falling due within one year

	2022 £	2021 £
Trade debtors	50,000	-
Other debtors	-	20,346
Prepayments and accrued income	<u>7,766</u>	<u>2,429</u>
	<u>57,766</u>	<u>22,775</u>

13. Creditors: amounts falling due within one year

	2022 £	2021 £
Bank loans and overdrafts (see note 14)	16,401	-
Trade creditors	211,334	14,633
Other creditors	25,135	9,449
Accruals and deferred income	<u>17,851</u>	<u>21,438</u>
	<u>270,721</u>	<u>45,520</u>

14. Loans

An analysis of the maturity of loans is given below:

	2022 £	2021 £
Amounts falling due within one year on demand:		
Bank overdrafts	<u>16,401</u>	<u>-</u>

Follicular Lymphoma Foundation
Notes to the Financial Statements - continued
for the year ended 31 December 2022

15. Analysis of net assets between funds

	Unrestricted funds £	Restricted fund £	2022 Total funds £	2021 Total funds £
Fixed assets	7,033	-	7,033	5,696
Current assets	1,455,609	(16,401)	1,439,208	1,439,249
Current liabilities	(270,721)	-	(270,721)	(45,520)
	<u>1,191,921</u>	<u>(16,401)</u>	<u>1,175,520</u>	<u>1,399,425</u>

16. Movement in funds

	At 1/1/22 £	Net movement in funds £	At 31/12/22 £
Unrestricted funds			
General fund	1,399,425	(207,504)	1,191,921
Restricted funds			
Restricted	-	(16,401)	(16,401)
TOTAL FUNDS	<u>1,399,425</u>	<u>(223,905)</u>	<u>1,175,520</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	1,986,260	(2,193,764)	(207,504)
Restricted funds			
Restricted	200,000	(216,401)	(16,401)
TOTAL FUNDS	<u>2,186,260</u>	<u>(2,410,165)</u>	<u>(223,905)</u>

Comparatives for movement in funds

	At 1/1/21 £	Net movement in funds £	At 31/12/21 £
Unrestricted funds			
General fund	356,337	1,043,088	1,399,425
TOTAL FUNDS	<u>356,337</u>	<u>1,043,088</u>	<u>1,399,425</u>

Follicular Lymphoma Foundation
Notes to the Financial Statements - continued
for the year ended 31 December 2022

16. Movement in funds - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	1,678,822	(635,734)	1,043,088
	<u>1,678,822</u>	<u>(635,734)</u>	<u>1,043,088</u>
TOTAL FUNDS	<u>1,678,822</u>	<u>(635,734)</u>	<u>1,043,088</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1/1/21 £	Net movement in funds £	At 31/12/22 £
Unrestricted funds			
General fund	356,337	835,584	1,191,921
Restricted funds			
Restricted	-	(16,401)	(16,401)
	<u>356,337</u>	<u>819,183</u>	<u>1,175,520</u>
TOTAL FUNDS	<u>356,337</u>	<u>819,183</u>	<u>1,175,520</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	3,665,082	(2,829,498)	835,584
Restricted funds			
Restricted	200,000	(216,401)	(16,401)
	<u>3,865,082</u>	<u>(3,045,899)</u>	<u>819,183</u>
TOTAL FUNDS	<u>3,865,082</u>	<u>(3,045,899)</u>	<u>819,183</u>

17. Related party disclosures

There were no related party transactions for the year ended 31 December 2022.

Follicular Lymphoma Foundation
Notes to the Financial Statements - continued
for the year ended 31 December 2022

18. Liability of members

The charitable company is limited by guarantee and has no share capital. in the event of the charitable company being wound-up, the liability in respect of the guarantee is limited to £10 per member of the charitable company during the time they are a member or within one year of ceasing to be a member, as stated in the Memorandum and Articles of Association.